Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for cancer. The company's lead product candidate, LCAR-B38M/JNJ-68284528, is a chimeric antigen receptor (CAR) T-cell therapy that is being developed for the treatment of multiple myeloma, a type of blood cancer. Legend Biotech was founded in 2014 as a subsidiary of GenScript Biotech Corporation and became an independent company in 2019. The company is headquartered in Shanghai, China and has operations in the United States and Europe.